# Phase 2b/3 Study of XAF5 Ointment for Steatoblepharon (Undereye Bags)

> **NCT02607683** · PHASE2,PHASE3 · COMPLETED · sponsor: **Topokine Therapeutics, Inc.** · enrollment: 300 (actual)

## Conditions studied

- Steatoblepharon

## Interventions

- **DRUG:** XAF5 (concentration A: 0.1%)
- **DRUG:** XAF5 (concentration B: 0.035%)
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT02607683
- **Lead sponsor:** Topokine Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-01
- **Primary completion:** 2016-09-19
- **Final completion:** 2016-10-31
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2017-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02607683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02607683, "Phase 2b/3 Study of XAF5 Ointment for Steatoblepharon (Undereye Bags)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02607683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*